Biotech VC dips in 3Q, but 2014 on track to beat 2013
This article was originally published in Scrip
Executive Summary
US venture capital investment in private biotechnology companies dipped to $1.05bn in the third quarter from $1.84bn in the second quarter, but venture funding in 2014 remains on track to beat the 2013 total and may exceed $5bn for the year – a total that hasn't been reached since 2008.